Guardian examines challenges of eliminating river blindness in Africa

NewsGuard 100/100 Score

The Guardian's "Global Development Professionals Network" blog "reports on the challenges of eliminating river blindness from Africa by 2025." "The implications of shift from disease control to elimination are considerable, as has been the case with the objective to eliminate onchocerciasis (better known as river blindness) by 2025, decided by the African Programme for Onchocerciasis Control (APOC) back in 2009," the blog writes, detailing elimination efforts against the disease since the 1970s. "Together, 20 years of vector control and 25 years of ivermectin treatment have brought onchocerciasis prevalence down to insignificant levels in many countries," the blog states. However, "the disease still exists," the blog notes and highlights a number of challenges to achieving elimination, such as raising funds for surveillance efforts and achieving universal treatment coverage due to "a potentially lethal reaction [to the drug] in patients infected with loa-loa, a parasite common in forest areas" (Filou, 12/17).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
IU researchers aim to develop a new therapy for glaucoma